Proof

We find the edge, then go past it.

We back ideas others overlook—and help make them inevitable.

We invest in frontier ideas across three broad domains: atoms, bits, and cells. Below are examples of how we've gone all-in—before they were obvious.

Atoms

An abundant nuclear future starts with the hardest problem—fuel.

We backed Atomic Alchemy before the world caught on—when isotopes were still overlooked as the linchpin for a nuclear renaissance. Energy, medicine, fusion—they all rely on enriched fuel. Without it, the future stalls. Not just a hard problem—the enabling constraint for everything nuclear.

ACQUIRED BY OKLO

"They were the only ones who didn't need to be convinced. They just got it."

— Thomas Eiden, Founder & CEO at Atomic Alchemy (acquired by Oklo)

Bits

Writing the rules of search for an AI-first world.

We backed Exa when rethinking search from first principles still sounded like science fiction. Before ChatGPT, before agents were cool—they were building AI-native search for the machine internet. Now, everyone else is playing catch-up.

"Most VCs need a wave to ride. Atypical backed us before the wave existed."

— Will Bryk, Co-Founder & CEO at Exa AI

Cells

Rewiring drug discovery: faster, smarter, human-first.

Parallel Bio rebuilt the drug development curve—starting with human biology on day one—when most of the world still used male inbred mice and crossed their fingers. This speeds up the loop: more tests, faster. Bad ideas fail earlier. Better models emerge. New biology gets discovered. The future of pharma is an experiment engine that compounds.

"They earned their seat by helping us think better—not by asking for updates."

— Robert DiFazio, Co-Founder & CEO at Parallel Bio

We back the weird ones.

The ones who just might be right.

Let's build something weird together.